TARO
Income statement / Annual
Last year (2024), Taro Pharmaceutical Industries Ltd.'s total revenue was $629.18 M,
an increase of 9.81% from the previous year.
In 2024, Taro Pharmaceutical Industries Ltd.'s net income was $53.87 M.
See Taro Pharmaceutical Industries Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$629.18 M |
$572.95 M |
$561.35 M |
$548.97 M |
$644.77 M |
$669.89 M |
$661.91 M |
$879.39 M |
$950.75 M |
$862.94 M |
| Cost of Revenue |
$324.20 M
|
$304.63 M
|
$268.23 M
|
$252.31 M
|
$245.04 M
|
$224.17 M
|
$198.41 M
|
$208.14 M
|
$171.79 M
|
$186.36 M
|
| Gross Profit |
$304.98 M
|
$268.32 M
|
$293.12 M
|
$296.66 M
|
$399.73 M
|
$445.72 M
|
$463.51 M
|
$671.25 M
|
$778.97 M
|
$676.59 M
|
| Gross Profit Ratio |
0.49
|
0.47
|
0.52
|
0.54
|
0.62
|
0.67
|
0.7
|
0.76
|
0.82
|
0.78
|
| Research and Development Expenses |
$64.54 M
|
$52.24 M
|
$54.54 M
|
$60.15 M
|
$59.78 M
|
$63.24 M
|
$70.42 M
|
$70.64 M
|
$71.16 M
|
$65.51 M
|
| General & Administrative Expenses |
$0.00
|
$85.09 M
|
$57.06 M
|
$52.81 M
|
$56.76 M
|
$83.44 M
|
$78.28 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$113.28 M
|
$56.62 M
|
$38.54 M
|
$36.66 M
|
$6.53 M
|
$9.91 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$218.94 M
|
$198.37 M
|
$113.68 M
|
$91.36 M
|
$93.41 M
|
$89.97 M
|
$88.20 M
|
$85.66 M
|
$92.37 M
|
$87.64 M
|
| Other Expenses |
$64.54 M
|
$2.46 M
|
$4.23 M
|
$2.89 M
|
$3.02 M
|
$1.81 M
|
$1.89 M
|
$11.21 M
|
$2.68 M
|
$2.74 M
|
| Operating Expenses |
$283.47 M
|
$250.61 M
|
$168.22 M
|
$151.51 M
|
$153.19 M
|
$153.21 M
|
$158.61 M
|
$156.30 M
|
$163.53 M
|
$153.15 M
|
| Cost And Expenses |
$607.67 M
|
$555.24 M
|
$436.44 M
|
$403.82 M
|
$398.23 M
|
$377.38 M
|
$357.02 M
|
$364.44 M
|
$335.31 M
|
$339.51 M
|
| Interest Income |
$56.19 M
|
$22.10 M
|
$8.19 M
|
$20.17 M
|
$33.65 M
|
$33.54 M
|
$19.93 M
|
$14.47 M
|
$12.60 M
|
$9.68 M
|
| Interest Expense |
$0.00
|
$1.25 M
|
$1.65 M
|
$1.36 M
|
$725,000.00
|
$256,000.00
|
$304,000.00
|
$131,000.00
|
$473,000.00
|
$928,000.00
|
| Depreciation & Amortization |
$31.09 M
|
$34.94 M
|
$25.92 M
|
$23.68 M
|
$6.55 M
|
$18.60 M
|
$16.50 M
|
$14.83 M
|
$14.85 M
|
$15.80 M
|
| EBITDA |
$38.40 M |
$52.65 M |
$164.89 M |
-$413.78 M |
$305.31 M |
$282.13 M |
$303.01 M |
$509.61 M |
$624.19 M |
$493.40 M |
| EBITDA Ratio |
0.08
|
0.09
|
0.37
|
1.33
|
0.39
|
0.42
|
0.54
|
0.58
|
0.66
|
0.57
|
| Operating Income Ratio |
0.03
|
0.03
|
0.33
|
1.28
|
0.38
|
0.44
|
0.46
|
0.59
|
0.65
|
0.61
|
| Total Other Income/Expenses Net |
$75.36 M
|
$20.50 M
|
-$47.06 M
|
-$536.22 M
|
$51.50 M
|
$60.66 M
|
-$10.64 M
|
$45.85 M
|
$22.35 M
|
$58.25 M
|
| Income Before Tax |
$82.67 M
|
$38.21 M
|
$77.86 M
|
-$391.07 M
|
$298.04 M
|
$356.85 M
|
$292.37 M
|
$560.80 M
|
$636.82 M
|
$581.68 M
|
| Income Before Tax Ratio |
0.13
|
0.07
|
0.14
|
-0.71
|
0.46
|
0.53
|
0.44
|
0.64
|
0.67
|
0.67
|
| Income Tax Expense |
$28.80 M
|
$12.77 M
|
$19.59 M
|
$9.67 M
|
$53.49 M
|
$74.73 M
|
$81.95 M
|
$103.78 M
|
$95.31 M
|
$96.06 M
|
| Net Income |
$53.87 M
|
$25.45 M
|
$58.27 M
|
-$400.74 M
|
$244.24 M
|
$281.78 M
|
$211.15 M
|
$456.36 M
|
$540.93 M
|
$484.26 M
|
| Net Income Ratio |
0.09
|
0.04
|
0.1
|
-0.73
|
0.38
|
0.42
|
0.32
|
0.52
|
0.57
|
0.56
|
| EPS |
1.43 |
0.68 |
1.55 |
-10.49 |
6.35 |
7.23 |
5.26 |
11.05 |
12.62 |
11.31 |
| EPS Diluted |
1.43 |
0.68 |
1.55 |
-10.49 |
6.35 |
7.23 |
5.26 |
11.05 |
12.62 |
11.31 |
| Weighted Average Shares Out |
$37.58 M
|
$37.58 M
|
$37.64 M
|
$38.21 M
|
$38.46 M
|
$38.99 M
|
$40.16 M
|
$41.30 M
|
$42.83 M
|
$42.83 M
|
| Weighted Average Shares Out Diluted |
$37.58 M
|
$37.58 M
|
$37.64 M
|
$38.21 M
|
$38.46 M
|
$38.99 M
|
$40.16 M
|
$41.30 M
|
$42.83 M
|
$42.83 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
